Journals / Üroonkoloji Bülteni / 2018 / Cilt: 17 - Sayı: 2

Evaluation of General Characteristics of Renal Cell Carcinoma Patients: A Single Center Experience

Pages
45–48
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

With early diagnosis, the partial nephrectomy rate might be increased.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Renal cancer (RC) accounts for 3.2% of all newly diagnosed cancers and approximately 90% of RC cases are renal cell carcinoma (RCC).
📊
Key Findings & Data:Materials and Methods: Patients who visited our medical oncology clinic and were diagnosed with RCC between January 1st, 2012 and May 31st, 2017 were evaluated retrospectively.
💡
Conclusion & Impact:With early diagnosis, the partial nephrectomy rate might be increased.
🔬Design:Research Article
📍Scope:2012 Verileri
⚙️Variables:Domain Parameters

Özet

Objective: Renal cancer (RC) accounts for 3.2% of all newly diagnosed cancers and approximately 90% of RC cases are renal cell carcinoma (RCC). Smoking and hypertension are the most important risk factors. The aim of our study was to evaluate the general characteristics of RCC patients in Bolu, Turkey. Materials and Methods: Patients who visited our medical oncology clinic and were diagnosed with RCC between January 1st, 2012 and May 31st, 2017 were evaluated retrospectively. Results: Eighty-one patients were diagnosed with RCC during the study period. The median age of the patients was 62 years (range: 38-87 years). Fifty-seven (70.4%) of the patients were male and 24 (29.6%) were female. Thirty patients (37.1%) were diagnosed incidentally. Forty-eight (59.3%) of the patients were smokers. The most common comorbidity was hypertension (58%). Radical nephrectomy was performed in 59 (72.8%) of the patients. The most common histological subtype was clear cell carcinoma (72.8%) and 39 (48.1%) were stage 1 when evaluated according to the stage of RCC. Of the 16 patients with metastatic disease, 11 (13.6%) received interferon therapy, and 5 patients (6.2%) refused treatment. After interferon treatment, 7 patients received targeted therapy with sunitinib/pazopanib as second-line treatment, 5 received everolimus as third-line treatment, and 3 received axitinib treatment as fourth-line treatment. Ten patients with bone metastasis underwent palliative radiotherapy. The median follow-up time of the patients was 21 months (0-123 months). Sixty-five patients (80.2%) survived this period. Conclusion: Smoking cessation and effective treatment of hypertension, preventable etiological factors of RCC, and incidental diagnosis of early RCC are very important. With early diagnosis, the partial nephrectomy rate might be increased.

🔖

Cite This Article

ÜYETÜRK, Ü., DUMAN, T. T., YILMAZ, B., KUCUKOZTAS, N., ÜYETÜRK, U. (2018). Evaluation of General Characteristics of Renal Cell Carcinoma Patients: A Single Center Experience. Üroonkoloji Bülteni, Cilt: 17 - Sayı: 2, 45–48. https://ajindex.com/articles/334397

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (17)

  1. Miller KD, Siegel RL, Lin CC, et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin 2016;66:271-289.
  2. Leibovich BC, Lohse CM, Crispen PL, et al. Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma. J Urol 2010;183:1309-1315.
  3. Moch H, Montironi R, Lopez-Beltran A, et al. Oncotargets in different renal cancer subtypes. Curr Drug Targets 2015;16:125-135.
  4. Ellati RT, Abukhiran I, Alqasem K, et al. Clinicopathologic Features of Translocation Renal Cell Carcinoma. Clin Genitourin Cancer 2017;15:112-116.
  5. Kabaria R, Klaassen Z, Terris MK. Renal cell carcinoma: links and risks. Int J Nephrol Renovasc Dis 2016;9:45-52.
  6. Ljungberg B, Campbell SC, Choi HY, et al. The epidemiology of renal cell carcinoma. Eur Urol 2011;60:615-621.
  7. White V, Marco DJT, Bolton D, et al. Trends in the surgical management of stage 1 renal cell carcinoma: findings from a population-based study. BJU Int 2017;120:6-14.
  8. De Meerleer G, Khoo V, Escudier B, et al. Radiotherapy for renal-cell carcinoma. Lancet Oncol 2014;15:170-177.
  9. Kothari G, Foroudi F, Gill S, et al. Outcomes of stereotactic radiotherapy for cranial and extracranial metastatic renal cell carcinoma: a systematic review. Acta Oncol 2015;54:148-157.
  10. Buti S, Bersanelli M, Sikokis A, et al. Chemotherapy in metastatic renal cell carcinoma today? A systematic review. Anticancer Drugs 2013;24:535-554.
  11. Daste A, Grellety T, Gross-Goupil M, Ravaud A. Protein kinase inhibitors in renal cell carcinoma. Expert Opin Pharmacother 2014;15:337-351.
  12. Altekruse SF, Dickie L, Wu XC, et al. Clinical and prognostic factors for renal parenchymal, pelvis, and ureter cancers in SEER registries: collaborative stage data collection system, version 2. Cancer 2014;120(Suppl 23):3826-3835.
  13. Türk A, Aslan H, Balaban M, ve ark. Böbreğin Renal Hücreli Kanserlerinde Klinik ve Histopatolojik Özellikler. J Kartal TR 2014;25:124-126.
  14. Atan A, Tuncel A, Aslan Y, ve ark. Böbrek Hücreli Kanser Hastalarında Tümör Sayısı Ve Adrenal Bez Tutulumunu Belirlemede Bilgisayarlı Tomografi Güvenilir Midir? Çok Merkezli Bir Çalışma. Türk Üroloji Dergisi 2005;31:329-334.
  15. Macleod LC, Hotaling JM, Wright JL, et al. Risk factors for renal cell carcinoma in the VITAL study. J Urol 2013;190:1657-1661.
  16. Visal Buturak Ş, Günal N, Özçiçek G, ve ark. Sigara bırakma polikliniğine başvuran hastaların sosyodemografik özellikleri ve sigara bağımlılık şiddetleri. Turk J Clin Lab 2016;7:72-76.
  17. Stojanovic M, Goldner B, Ivkovic D. Renal ce